Fate Therapeutics Reports Third Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- UBS Reiterates Buy Rating on Snowflake Inc. (SNOW)
Cowen Sees High Probability of Positive Data ASH at from Fate Therapeutics (FATE)
November 4, 2015 7:12 AM ESTCowen analyst Boris Peaker reiterated an Outperform rating on Fate Therapeutics (NASDAQ: FATE) and sees high probability of positive data at ASH.
Peaker commented, "Fate provided a pipeline update on its 3Q15 call as well as an overview of its... More
Fate Therapeutics (FATE) Tops Q3 EPS by 6c
November 3, 2015 4:28 PM ESTFate Therapeutics (NASDAQ: FATE) reported Q3 EPS of ($0.24), $0.06 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $1 million versus the consensus estimate of $430 thousand.
For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.
... More